Biomarkers are critical for diagnosing cancer, predicting treatment response, and monitoring disease progression. However, finding reliable biomarkers is challenging. Many biomarkers lack specificity, leading to false positives or negatives. The heterogeneity of tumors further complicates the identification of universal biomarkers. Additionally, the validation and standardization of new biomarkers require extensive clinical trials, which are both time-consuming and expensive.
